<Suppliers Price>

Levosimendan

Names

[ CAS No. ]:
141505-33-1

[ Name ]:
Levosimendan

[Synonym ]:
Levosimedan
Mesoxalonitrile (-)-[p-[(R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazone
({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)malononitrile
({4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-3-pyridazinyl]phenyl}hydrazono)malononitrile
(R)-[[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile
Propanedinitrile, 2-[2-[4-[(4R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-
Levosimendan
(R)-(-)-2-[4-(4-methyl-6-oxo-1,4,5,6,-tetrahydropyridazin-3-yl)phenylhydrazono]propanedinitrile
MFCD00867135
Simdax
(2-{4-[(4R)-4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazinyliden)propandinitril
2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
(R)-Simendan

Biological Activity

[Description]:

Levosimendan(OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.Target: OthersLevosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy [1]. The cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators [2]. Levosimendan might reduce mortality in cardiac surgery and cardiology settings of adult patients [3].

[Related Catalog]:

Signaling Pathways >> Autophagy >> Autophagy
Research Areas >> Cardiovascular Disease

[References]

[1]. Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245.

[2]. Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7.

[3]. Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46.


[Related Small Molecules]

Rapamycin (Sirolimus) | MG-132 | Cycloheximide | 3-Methyladenine | LY294002 | TAK-242 | (+)-JQ1 | SB203580 | Pyrazolanthrone (SP600125) | U0126-EtOH | Actinomycin D | Chloroquine diphosphate | CHIR-99021 (CT99021) | MK-2206 2HCl | Dorsomorphin dihydrochloride

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Melting Point ]:
216-219ºC (dec.)

[ Molecular Formula ]:
C14H12N6O

[ Molecular Weight ]:
280.285

[ Exact Mass ]:
280.107269

[ PSA ]:
113.43000

[ LogP ]:
0.59

[ Index of Refraction ]:
1.673

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H312-H332

[ Precautionary Statements ]:
P280

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
R20/21/22

[ Safety Phrases ]:
S36/S37

[ RIDADR ]:
NONH for all modes of transport

[ RTECS ]:
TY1570210

Synthetic Route

Precursor & DownStream

Articles

Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro.

Thromb. Haemost. 113(2) , 350-62, (2015)

Levosimendan is a positive inotropic drug for the treatment of acute decompensated heart failure (HF). Clinical trials showed that levosimendan was particularly effective in HF due to myocardial infar...

Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene.

Skelet. Muscle 5 , 12, (2015)

Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is characterized by generalized skeletal muscle weakness, often from birth. To date, no therapy exists that enhances the con...

A Bayesian network meta-analysis on the effect of inodilatory agents on mortality.

Br. J. Anaesth. 114 , 746-56, (2015)

Inodilators are commonly used in critically ill patients, but their effect on survival has not been properly studied to date. The objective of this work was to conduct a network meta-analysis on the e...


More Articles


Related Compounds